General Psychiatry (Oct 2021)

Effectiveness of E-SBIRT intervention in community healthcare institution in China: study proposal for a randomised controlled trial

  • Lei Zhang,
  • Min Zhao,
  • Jiang Long,
  • Wei Sun,
  • Jing Zhai,
  • Rao Fu,
  • Chenxin Yuan,
  • Wenzheng Wang,
  • Qun Guan,
  • Xiaojun Wu

DOI
https://doi.org/10.1136/gpsych-2021-100486
Journal volume & issue
Vol. 34, no. 5

Abstract

Read online

Background Many studies have demonstrated the effectiveness of Screening, Brief Intervention and Referral to Treatment (SBIRT) in addressing substance use problem. However, owing to the shortage of counsellors, it has not been widely used in China. With the development of smart medicine, we developed a web-based electronic SBIRT (E-SBIRT) program and explored the effectiveness of E-SBIRT in reducing substance use in China.Methods A randomised controlled trial will be conducted in primary healthcare institutions. Four primary healthcare institutions will be selected and randomly divided into an intervention group and a control group (each institution will recruit 60 participants, and in total, 240 participants will be recruited). The control group will get a pamphlet of drug abuse prevention, and the intervention group will get the E-SBIRT intervention and the pamphlet. Both groups will receive baseline and follow-up assessment at 1 and 3 months after the intervention. The primary outcome is the change in scores on the Alcohol, Smoking and Substance Use Involvement Screening Test, and the secondary outcomes include changes in motivation, depression, anxiety, positive/negative emotion, self-esteem, addiction knowledge and addiction severity index.Conclusions If the ‘E-SBIRT’ program is found to be effective, it will be an accessible, affordable and widely implementable intervention to help participants at moderate risk of substance use to reduce their consumption. The potential benefit is to provide early intervention to high-risk patients in time and reduce the harmful consequences to individuals and society.Trial registration number NCT03452241.